沙利度胺联合用药抗肿瘤研究进展

摘要/Abstract

摘要： 20 世纪60 年代沙利度胺因其具有致畸性而退出历史舞台, 后来研究发现其致畸现象的背后是抗血管生成的作用。而抗血管生成作用这时已被学术界认为是对抗肿瘤生成的一个重要因素。后来, 研究人员又发现了沙利度胺的其他抗肿瘤机制, 这样沙利度胺便被作为一种极具潜力的抗肿瘤药物而被广泛研究。本文重点综述了沙利度胺的抗肿瘤作用机制以及它与其他药物联合用药用于治疗实体瘤的研究进展。

关键词: 沙利度胺, 抗肿瘤, 联合用药

Abstract: Following the reports of its teratogenicity, thalidomide was banned from the market in the 1960s.Later, researches discovered the teratogenicity was caused by inhibiting angiogenesis, and at that time the antiangiogenesis effect was considered an important factor in anti-tumour.Since then, many other anti-tumour mechanisms of thalidomide had been revealed and thalidomide was considered a kind of potential antitumor drug and was researched widely.This article focuses on the anti-tumour mechanisms of thalidomide and its use in combination therapy for the treatment of solid tumor.

Key words: thalidomide, anti-tumour, combination therapy

中图分类号:

R730

俞珊, 季晖. 沙利度胺联合用药抗肿瘤研究进展[J]. 中国临床药理学与治疗学, 2009, 14(2): 230-236.

YU Shan, JI Hui. Research progress of thalidomide in combination therapy for the treatment of tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 230-236.

参考文献

[1] Kedar I, Mermershtain W, Ivgi H.Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy[J].Int J Cancer, 2004, 110(2):260-265.
[2] Marriott JB, Clarke IA, Czajka A, et al.A novel subclass of thalidomide analogues with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins[J].Cancer Res, 2003, 63(3):593-599.
[3] Singhal S, Mehta J, Desikan R, et al.Antitumor activity of Thalidomide in refractory multiple myeloma[J].N Engl J Med, 1999, 342(1):1565-1571.
[4] Barlogie B, ZangariM, Spencer T, et al.Thalidomide in the management of multipie myeloma[J].Semin Hematol, 2001, 38(3):250-259.
[5] 陈莉莉, 王友群, 江文华, 等.沙利度胺联合化疗治疗多发性骨髓瘤的临床观察[J].中国医院药学杂志, 2005, 25(8):755.
[6] Dingli D, Rajkumar SV, Nowakowski GS, et al.Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multip le myeloma not undergoing upfront autologous stem cell transp lantation:a phase Ⅱ trial [J].Haematologica, 2005, 90(12):1650.
[7] Rajkumar SV, Blood E, Vesole D, et al.Phase Ⅲ clinical trial of thalidomide plus dexamet hasone compared with dexamet hasone alone in newly diagnosed multiple myeloma:a clinial trialcoordinated by the eastern cooperative oncology group[J].J Clin Oncol, 2006, 24(3):431-436.
[8] Terpos E, Kastritis E, Roussou M, et al.The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis[J].Leukemia, 2008, 9 (4):231.
[9] Fine HA, Wen PY, Maher EA, et al.Phase Ⅱ trial of thalidomide and carmustine for patients with recurrent high-grade gliomas[J].J Clinoncol, 2003, 21(12):2299.
[10] Banmann F.Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme[J].J Neurooncol, 2004, 67(122):191.
[11] Murphy S, Davey RA, Gu XQ, et al.Enhancement of cisplatin efficacy by thalidomide in a rat gliosarcomamodel [J].J Neurooncol, 2007, 85(2):181-184.
[12] Riva M, Imbesi F, Beghi E, et al.Temozolomide and thalidomide in the treatment of glioblastoma multiforme [J].Anticancer Res, 2007, 27(2):1067-1071.
[13] Horne MK, Figg WD, Arlen P, et al.Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer[J].Pharmacotherapy, 2003, 23(3):315-318.
[14] Dahut WL, Gulley JL, Arlen PM, et al.Randomized phase II trial of docetaxel plus thalidomide in androgenindependent prostate cance[J].J Clin Oncol, 2004, 22(13):2532-2539.
[15] Romero S, Stanton G, DeFelice J, et al.Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy[J].Urol Oncol, 2007, 25(4):284-290.
[16] Hwu WJ, Krown SE, Panageas KS, et al.Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial[J].J Clin Oncol, 2002, 20 (11):2610-2615.
[17] Laber DA, Okeke RI, Arce-Lara C, et al.A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma[J]. J Cancer Res Clin Oncol, 2006, 132(9):611-615.
[18] Mita MM, Rowinsky EK, Forero L, et al.A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma [J]. Cancer Chemother Pharmacol, 2007, 59(2):165-167.
[19] Hada M, Horiuchi T.A case report of chemot herapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer[J].No Shinkei Geka, 2005, 33(10):1021-1026.
[20] Pujol J, Breton J, Gervais R, et al.A prospective randomised phase Ⅲ, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT) [J].Lung Cancer, 2005, 49(2):159.
[21] Lee SM, James L, Buchler T, et al.Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer [J].Lung Cancer, 2008, 59(3):364.
[22] 何秋山, 易铁男, 罗斌, 等.NP 方案联合与不联合沙利度胺治疗晚期非小细胞肺癌的临床随机对照研究[J].中国肺癌杂志, 2008, 11(2):264-267.
[23] Amato RJ.Thalidomide therapy for renal cell carcinoma [J].Crit Rev Oncol Hematol, 2003, 46(5):59.
[24] SchraderA J, Heidenreich A, Hegele A, et al.App lication of thalidomide interleukin-2 in immunochemotherapyrefractory metastatic renal cell carcinoma[J].Anticancer Drugs, 2005, 16(5):581.
[25] Clark PE, Hall MC, Miller A, et al.Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma[J].Urology, 2004, 63(6):1061-1065.
[26] Vaishampayan UN, Heilbrun LK, Shields AF, et al. Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma[J].Invest New Drugs, 2007, 25 (1):69-75.
[27] Govindarajan R.Irinotecan thalidomide in metastatic colorectal cancer[J].Oncology, 2002, 16(3):23.
[28] 陈晓泉, 姜凤先.卡培他滨联合沙利度胺化疗对结直肠癌组织胸苷磷酸化酶表达的影响[J].现代肿瘤医学, 2007, 15(15):674.
[29] Zhang HG, Li J, Qin SK, et al.A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer[J].Zhouhua Zhong Liu Za Zhi, 2007, 29(3):228-231.
[30] McCollum AD, Wu B, Clark JW, et al.The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer[J].J Clin Oncol, 2006, 29(1):40.
[31] Wang TE.Salvage therapy for hepatocellular carcinoma with thalidomide[J].World J Gastroenterol, 2004, 10 (5):649.
[32] 郑伟生, 陈强, 叶韵斌, 等.沙利度胺对原发性肝癌介入治疗后肌体免疫功能的影响[J].肿瘤基础与临床, 2007, 20(2):145.
[33] Zhang ZL, Liu ZS, Sun Q.Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice[J].Chin Med J (Engl), 2005, 118(20):1688-1691.
[34] Gordinier ME, Dizon DS, Weitzen S, et al.Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer[J].J PalliatMed, 2007, 10(1):61-66.
[35] Laurenti L, Piccioni P, Tarnani M, et al.Low-dose thalidomide in combination with oral fludarabine and cy clophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia[J].Leuk Res, 2007, 31(2):253-256.
[36] Treon SP, Soumerai JD, Branagan AR, et al.Thalidomide and rituximab in Waldenstrom's macroglobulinemia [J]. Blood, 2008, 112(12):4452-4457.